Navigation Links
Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Date:2/5/2009

WALTHAM, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the third quarter of fiscal year 2009, ended December 31, 2008. Total revenue for the quarter was $6,018,000 compared to $4,664,000 for the third quarter of fiscal year 2008. Total revenue was comprised of Protein A product revenue, and royalty and other revenue. Product revenue for the quarter was $3,294,000 and royalty and other revenue was $2,724,000, comprised primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia(R) (abatacept) and grant revenue from the Muscular Dystrophy Association.

Operating expenses for the third quarter of fiscal year 2009 were $6,556,000 compared to $5,663,000 for the same period in fiscal year 2008. This increase in operating expenses of $893,000 was primarily the result of increased spending associated with advancement of our Phase 3 clinical trial of RG1068 for pancreatic imaging, and initiation of our Phase 2b clinical trial of RG2417 for bipolar depression, as well as increased research and development expenses associated with our program to identify a clinical candidate for Friedreich's ataxia. These increases in spending were partially offset by reductions in legal and other selling, general and administrative expenses.

The net income for the quarter was $18,000 or $0.00 per diluted share, compared to a net loss for the same quarter of fiscal year 2008 of $242,000 or $0.01 per diluted share. Cash, cash equivalents and marketable securities as of December 31, 2008 were $64,509,000 compared to $60,589,000 as of March 31, 2008.

"We are pleased to have advanced our pipeline and achieved strong revenue growth during a quarter marked by continued global financial turmoil," stated Walter C. Herlihy, President and Chief Executive Officer of
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
3. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
4. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
5. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
6. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
7. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
8. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
9. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
10. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech Medical SAS ... in Orthopedics, announced today the acquisition of Turner Medical, Inc ., thus ... surgical instruments to the Spine Industry. The acquisition of Turner Medical ideally supplements ...
(Date:7/1/2015)... Colo. and BANGALORE, India ... global genomic profiling company that uses next generation sequencing ... of Scott A. Storrer as chief executive ... CEO, he will be responsible for all strategy, business ... Chandru , who has served as Strand,s chairman and ...
(Date:7/1/2015)... July 1, 2015 InferMed ... will ... evidence-based clinical s olutions suite   ... medical information products and services, announced today the acquisition of  ... support (CDS) technology company. InferMed,s Arezzo technology supports ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... to take part in the first half of “Integrative Biotechnology,” an applied biotechnology ... established in summer 2014, this course combines students from both universities and is ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2
... Firms Recommend Pharmion ... merger with Celgene Special Meeting ... Corp. Urges All Shareholders to Vote FOR the Proposed Merger, ... ) today announced that Institutional Shareholder Services,(ISS) has recommended that ...
... and Vaccine Immunology, ANN ARBOR, Mich., Feb. 26 ... have demonstrated their nasally,delivered vaccinia vaccine can protect animals ... without the safety risks of,current vaccines for smallpox. Vaccinia ... it., The new vaccine confers a high level ...
... Switzerland, February 26 Arpida Ltd.,(SWX: ARPN) today reported ... for intravenous iclaprim in its first indication,complicated Skin and ... few weeks., Arpida has agreed with the U.S. ... a rolling process. Using a ,rolling NDA, allows modules,within ...
Cached Biology Technology:ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 2ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 3Nasal Vaccine for Smallpox Confers High Levels of Immunity Without Safety Risks 2Nasal Vaccine for Smallpox Confers High Levels of Immunity Without Safety Risks 3Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 2Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 3
(Date:6/24/2015)... 2015 Research and ... the "Huawei Ascend Mate 7 Fingerprint Sensor ... offering. Huawei,s technological choice for the ... than Apple,s and Samsung,s one. The Ascend Mate ... Fingerprint Cards, a main actor in capacitive sensing ...
(Date:6/23/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/vq2k2f/bodyworn ... "Body-Worn Temperature Sensors Market - Global Industry Analysis, ... 2020" report to their offering. ... body-worn temperature sensors market. The global body-worn temperature ... of types, care setting, patient demographic, applications and ...
(Date:6/18/2015)... , June 18, 2015 This report ... Million by the following Product Segments, which includes Immunoassay ... Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay ... US, Canada , Japan ... Asia-Pacific , Latin America , ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... discovered a super-charged methane seep in the ocean off New ... in much more methane escaping from the ocean floor into ... gas 23 times more potent than carbon dioxide at warming ... water, the scientists say. Thus it will not make it ...
... patients, it,s not the primary tumor that is deadly, but ... tumor to secondary locations throughout the body that is the ... is how to stop or fight metastasis. Previous ... molecular change when they leave the primary tumor a ...
... under a third of young Swiss men prefer beer when ... their alcohol consumption in the form of the beverage. Far ... between the preference for particular alcoholic beverages and a riskier ... from the Institute of Social and Preventive Medicine at the ...
Cached Biology News:Study finds novel worm community affecting methane release in ocean 2Study finds novel worm community affecting methane release in ocean 3New evidence that cancer cells change while moving throughout body 2Young beer-drinkers binge-drink more frequently 2
... Fluoroskan Ascent is a ... flexibility for all kinds of ... research and for clinical applications. ... biology are all important application ...
... SpeedVac Concentrator, the SPD series takes the ... modern twist., The SPD121P SpeedVac comes equipped ... optimizing runs; preventing samples from freezing; and ... the end-users preset level., Standard features on ...
... desktop unit ideal for use in laboratories with ... speed set at 12 rpm , Temperature ... Bottle capacity of four 35 x 150mm bottles, ... bottles , Consistent, repeatable results achieved with ...
... Savant SpeedVac Concentrators set the standard for centrifugal ... uses a combination of centrifugal force, heat and ... run., SC110A comes equipped with:, , TEFLON-coated ... , Three ...
Biology Products: